BioAge Labs (BIOA) EBITDA Margin (2025 - 2026)
BioAge Labs (BIOA) reported EBITDA Margin of 915.4% for Q1 2026, up 21802.0% on a YoY basis from N/an in Q1 2025, and up 0.87% sequentially from 923.42% in Q4 2025.
BioAge Labs (BIOA) EBITDA Margin (2025 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of EBITDA Margin data on file, last reported at 915.4% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 21802.0% year-over-year to 915.4%; the trailing twelve-month figure through Mar 2026 stood at 985.93% (up 465342.0% YoY), and the FY2025 full-year result was 1031.46%, changed N/A from the prior year.
- EBITDA Margin climbed to 915.4% in Q1 2026, from 923.42% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 915.4% in Q1 2026 to a low of 1133.43% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | -915.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -915.40% |
| Dec 31, 2025 | -923.42% |
| Sep 30, 2025 | -1,126.58% |
| Jun 30, 2025 | -1,026.99% |
| Mar 31, 2025 | -1,133.43% |